

# **NEUROENDOCRINE TUMOURS: THE CUTTING EDGE AND A GLIMPSE INTO THE FUTURE**

**Do minimal access and robotic surgery  
bring benefit to neuroendocrine tumours?**

[m.falconi@univpm.it](mailto:m.falconi@univpm.it)

U.O.C. Chirurgia del Pancreas

Università Politecnica delle Marche

Ancona (ITALY)


**Madrid, September 28, 2014**

# Disclosure


I have no conflicts of interest to declare but that I am a surgeon who ever performed neither a laparoscopic nor a robotic operation by himself

M Falconi

# The cutting edge of surgery



**Laparoscopic surgery**




**Robotic surgery**

# A glimpse into the future



**Robotic surgery**



**Laparoscopic surgery**

# Imagine above us a blue sky ... (modified from John Lennon)



Diagnosis of appendicitis



Here Apollo 2020, we have a problem!!!



Here Houston, no problem at all we have a program of robotic surgery!!!



# What is the actual room for mini-invasive surgery (MIS) in NENs world?

- ✓ Anatomical districts
- ✓ Surgical skill (learning curve)
- ✓ Underlying disease (size and stage)
- ✓ EBM results (RCTs)

# **NENs are a very large family**

- Adrenalectomy
- Appendectomy
- Colon

# MIS **[and]** NENs

- Adrenalectomy ✓(size and extension)
- Appendectomy ✓
- Colon ✓



## **A first conclusion**

There are no reasons for thinking that a MIS approach should follow different rules when a surgeon deals with a NEN located in organs for which such an approach is already established for either a benign or a malignant disease

# NENs are a very large family

- Adrenalectomy ✓
- Appendectomy ✓
- Colon ✓
- Small bowel ?

# Jejunum & ileum NENs

Well-differentiated endocrine cell carcinoma of ileum treated by laparoscopy-assisted surgery--a case report.

Sasada S, Ojima Y, Nishizaki M, Harano M, Matsukawa H, Aoki H, Shiozaki S, Ohno S, Ninomiya M, Matsuura H, Takakura N.

Hiroshima J Med Sci. 2010 Jun;59(2):35-8.

# A recent larger contribution

## Surgery for small-bowel neuroendocrine tumors: Is there any benefit of the laparoscopic approach?

Marleny N. Figueiredo • Léon Maggiori • Sébastien Gaujoux • Anne Couvelard •  
Nathalie Guedj • Philippe Ruszniewski • Yves Panis

# A recent larger contribution

**Table 1** Comparison of clinical and operative findings between the open surgery group and the laparoscopy group

	Open surgery (n = 61)	Laparoscopy (n = 12)	p value
Age [years; median (range)]	56.5 (27–79)	54 (40–60)	0.08

**Conclusion** Complete resection of primary SBNE tumors with or without liver metastasis is associated with good long-term survival. In selected patients, laparoscopy for SBNE tumors is feasible and associated with a shorter hospital stay than laparotomy.

Operative time [min; median (IQR)]	100 (75–100)	100 (75–100)	0.001
Length of resected specimen [cm; median (IQR)]	47.5 (27.5–70)	19 (14.5–28)	0.009
Postoperative morbidity [n (%)]			0.95
Overall	13 (21.3)	3 (25)	
Severe	4 (6.6)	1 (8.3)	
Length of stay [days; median (range)]	8 (2–34)	6 (4–10)	0.003

# A contribution **with some tricks**

**Table 1** Comparison of clinical and operative findings between the open surgery group and the laparoscopy group

	Open surgery ( <i>n</i> = 61)	Laparoscopy ( <i>n</i> = 12)	<i>p</i> value
Age [years; median (range)]	56.5 (27–79)	54 (40–60)	0.08
Gender [male; <i>n</i> (%)]	34 (55.7)	6 (50)	0.75
BMI [median (IQR)]	24 (21.9–27.4)	26.6 (22.6–28.4)	0.49
Secreting tumor [ <i>n</i> (%)]	25 (41)	1 (8.3)	0.07
Presence of nodes at diagnosis [ <i>n</i> (%)]	52 (85.2)	3 (25)	<0.001
Liver metastases [ <i>n</i> (%)]	42 (68.9)	1 (8.3)	<0.001
Type of surgery [ <i>n</i> (%)]			0.008
Small-bowel resection	36 (59)	2 (16.7)	
Ileocelectomy	18 (29.5)	7 (58.3)	
SB + IC	4 (6.6)	3 (25)	
Not known/not described	3 (4.9)	–	
Operative time [min; median (IQR)]	180 (130–300)	145 (120–160)	0.34
Length of resected specimen [cm; median (IQR)]	47.5 (27.5–70)	19 (14.5–28)	0.009
Postoperative morbidity [ <i>n</i> (%)]			0.95
Overall	13 (21.3)	3 (25)	
Severe	4 (6.6)	1 (8.3)	
Length of stay [days; median (range)]	8 (2–34)	6 (4–10)	0.003

# A contribution **with some tricks**

**Table 1** Comparison of clinical and operative findings between the open surgery group and the laparoscopy group

	Open surgery ( <i>n</i> = 61)	Laparoscopy ( <i>n</i> = 12)	<i>p</i> value
Age [years; median (range)]	56.5 (27–79)	54 (40–60)	0.08
Gender [male; <i>n</i> (%)]	34 (55.7)	6 (50)	0.75
BMI [median (IQR)]	24 (21.9–27.4)	26.6 (22.6–28.4)	0.49
Secreting tumor [ <i>n</i> (%)]	25 (41)	1 (8.3)	0.07
Presence of nodes at diagnosis [ <i>n</i> (%)]	52 (85.2)	3 (25)	<0.001
Liver metastases [ <i>n</i> (%)]	42 (68.9)	1 (8.3)	<0.001
Type of surgery [ <i>n</i> (%)]			0.008
Small-bowel resection	36 (59)	2 (16.7)	
Ileocelectomy	18 (29.5)	7 (58.3)	
SB + IC	4 (6.6)	3 (25)	
Not known/not described	3 (4.9)	–	
Operative time [min; median (IQR)]	180 (130–300)	145 (120–160)	0.34
Length of resected specimen [cm; median (IQR)]	47.5 (27.5–70)	19 (14.5–28)	0.009
Postoperative morbidity [ <i>n</i> (%)]			0.95
Overall	13 (21.3)	3 (25)	
Severe	4 (6.6)	1 (8.3)	
Length of stay [days; median (range)]	8 (2–34)	6 (4–10)	0.003

# A contribution **with some tricks**

**Table 1** Comparison of clinical and operative findings between the open surgery group and the laparoscopy group

	Open surgery ( <i>n</i> = 61)	Laparoscopy ( <i>n</i> = 12)	<i>p</i> value
Age [years; median (range)]	56.5 (27–79)	54 (40–60)	0.08
Gender [male; <i>n</i> (%)]	34 (55.7)	6 (50)	0.75
BMI [median (IQR)]	24 (21.9–27.4)	26.6 (22.6–28.4)	0.49
Secreting tumor [ <i>n</i> (%)]	25 (41)	1 (8.3)	0.07
Presence of nodes at diagnosis [ <i>n</i> (%)]	52 (85.2)	3 (25)	<0.001
Liver metastases [ <i>n</i> (%)]	42 (68.9)	1 (8.3)	<0.001
Type of surgery [ <i>n</i> (%)]			0.008
Small-bowel resection	36 (59)	2 (16.7)	
Ileocelectomy	18 (29.5)	7 (58.3)	
SB + IC	4 (6.6)	3 (25)	
Not known/not described	3 (4.9)	–	
Operative time [min; median (IQR)]	180 (130–300)	145 (120–160)	0.34
Length of resected specimen [cm; median (IQR)]	47.5 (27.5–70)	19 (14.5–28)	0.009
Postoperative morbidity [ <i>n</i> (%)]			0.95
Overall	13 (21.3)	3 (25)	
Severe	4 (6.6)	1 (8.3)	
Length of stay [days; median (range)]	8 (2–34)	6 (4–10)	0.003



# NENs are a very large family

- Adrenalectomy ✓
- Appendectomy ✓
- Colon ✓
- Small bowel ✗
- Pancreas ?

# Pancreas [and] Surgery [and] NENs

- ✓ Pancreaticoduodenectomy
- ✓ Middle pancreatectomy
- ✓ Distal pancreatectomy ( $\pm$  splenectomy)
- ✓ Enucleation
- ✓ Total Pancreatectomy

# I am a lucky man: somebody else did my job!


## REVIEW ARTICLE

### Laparoscopic versus open pancreas resection for pancreatic neuroendocrine tumours: a systematic review and meta-analysis


Panagiotis Drymouisis<sup>1</sup>, Dimitri A. Raptis<sup>2\*</sup>, Duncan Spalding<sup>1\*</sup>, Laureano Fernandez-Cruz<sup>3</sup>, Deepak Menon<sup>1</sup>, Stefan Breitenstein<sup>4</sup>, Brian Davidson<sup>5</sup> & Andrea Frilling<sup>1</sup>

<sup>1</sup>Department of Surgery and Cancer, Hammersmith Hospital Campus, Imperial College London, London, UK, <sup>2</sup>Department of Visceral and Transplantation Surgery, University Hospital Zurich, Zurich, Switzerland, <sup>3</sup>Bilio-Pancreatic Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain, <sup>4</sup>Department of Surgery, Kantonsspital Winterthur, Winterthur, Switzerland and <sup>5</sup>Department of Surgery, Royal Free Campus, University College London Medical School, London, UK



# The usual PRISMA flow chart




# ... and interesting results on operative time (a)





# ... and interesting results on operative time (a) and blood loss (b)



# ... and interesting results on overall complication (a)




# ... and interesting results on overall complication (a) and PF (b)






# ... resulting in a shorter LOS



# Wonderful: we are at the top of EBM!!!



but again with some tricks (sic!)

Authors	Year	Study type	Type of PNET	Period of patient recruitment	Country	Patients, n	IPS, n	OPS, n	Conversion, n
Espana-Gomez <i>et al.</i> <sup>19</sup>	2009	Retrospective	Insulinomas	1995–2007	Spain	34	21	13	7
Gumbs <sup>20</sup>	2008	Retrospective	Functioning (23%) Non-functioning (77%)	1992–2006	France	31	18	13	1
Hu <i>et al.</i> <sup>21</sup>	2011	Retrospective	Insulinomas	2000–2005	China	89	43	46	2
Karaliotas & Sgourakis <sup>22</sup>	2009	Retrospective	Insulinomas	1994–2008	Greece	12	5	7	1
Kazanjian <i>et al.</i> <sup>23</sup>	2006	Retrospective	Functioning (29%) Non-functioning (71%)	1990–2005	USA	70	4	66	NR
Liu <i>et al.</i> <sup>24</sup>	2007	Retrospective	Insulinomas	2000–2006	China	48	7	41	3
Lo <i>et al.</i> <sup>25</sup>	2004	Retrospective	Insulinomas	1999–2002	China	10	4	6	0
Roland <i>et al.</i> <sup>26</sup>	2008	Retrospective	Insulinomas	1998–2007	USA	37	22	15	2
Sa Cunha <i>et al.</i> <sup>27</sup>	2006	Retrospective	Insulinomas	1999–2005	China	21	12	9	3
Zerbi <i>et al.</i> <sup>28</sup>	2011	Prospective	Functioning (27%) Non-functioning (73%)	2004–2007	Italy	262	21	241	NR
Zhao <i>et al.</i> <sup>29</sup>	2011	Retrospective	Insulinomas	1990–2010	China	292	46	246	19
<b>Total</b>						<b>906</b>	<b>203</b>	<b>703</b>	

10 retrospective, 1 prospective no RCT, 0 RCT

# The surgeons and statistic: a new love?



# To make the story short

- ✓ More systematic reviews and meta-analyses than patients comparing
  - ✓ open vs lap; lap vs. rob; rob vs. lap for either PD or DP
- ✓ No one RCT either for laparoscopy or robot
- ✓ Usual words in the conclusion “the technique is”
  - ✓ feasible
  - ✓ safe
  - ✓ same pancreas-related complications
  - ✓ some trouble as regard the cost effectiveness
  - ✓ but usually less LOH

# Pancreas [and] Surgery [and] NENs

- ✓ Reproducible in any place?
- ✓ Possible biases:
  - ✓ Patients selection
  - ✓ Intention to treat analysis (conversion rate)
  - ✓ Fast-track postoperative protocol also in historical series of open resection?

**Needs for well designed RCTs!!!**

# To be unbiased and rational in a cutting edge era:

## pancreas [and] surgery [and] NENs

✓ Pancreaticoduodenectomy

✓ Middle pancreatectomy

Pancreatic and/or biliary anastomosis

✓ Distal pancreatectomy ( $\pm$  splenectomy)

✓ Enucleation

✓ Total Pancreatectomy

Biliary anastomosis

# The MIS cutting edge for a “human” pancreatic surgeon: size as possible cut-off

Type of approach	open	laparoscopy <sup>1</sup>	robotic <sup>1</sup>
Distal pancreatectomy	> 4-5 cm	< 4-5 cm but high surgical skill	
Enucleation	deep in the head	superficial providing Lap IOUS	superficial providing Lap IOUS
PD	ever	but high surgical skill	
Middle pancreatectomy	ever	but high surgical skill	


<sup>1</sup> providing specific programs and minimal expertise



# Why Lap pancreatectomies are not routinely performed?

**Not very “natural”:**

- ✓ Bi-dimensional vision
- ✓ Minimal tactile perception
- ✓ Arms and head in a forced position



# Advantages of the robot

More “natural”:


- ✓ Three-dimensional vision
- ✓ Enhanced dexterity through articulated instruments



# Advantages of the robot

## More “natural”:

- ✓ Three-dimensional vision
- ✓ Enhanced dexterity through articulated instruments
- ✓ Higher magnification of the surgery site
- ✓ Arms that provide fixed traction and exposure



# Do minimal access and robotic surgery bring benefit to neuroendocrine tumours?

- Adrenalectomy ✓
- Appendectomy ✓
- Colon ✓
- Pancreas ✓
- Small bowel ✗

# Some truths over all the truths

1. MIS approach requires specific experience on different organs and diseases
2. NENs require both single expertise and a MDT before any surgical skill
3. The surgeon must offer the “right” operation whichever the approach